SAN CARLOS, Calif., Oct. 28, 2022 (GLOBE NEWSWIRE) — Medical robotics innovator Noah Medical has provided physicians attending the 2022 American College of Chest Physicians meeting with an overview of study data documenting its tool high in lesion rate. This subset of data and the demonstrations of the Galaxy system have received excellent reviews from the interventional pulmonology community.
The Galaxy system is designed to provide a fully integrated solution for navigational robotic bronchoscopy, which can help improve the localization accuracy and diagnosis of pulmonary nodules using its proprietary TiLT+ Technology™. With its single-use bronchoscope and small footprint, it is also designed to improve efficiency and reduce cross-contamination.
The full data set from Noah’s MATCH study validating Galaxy’s TiLT technology and its ability to achieve 100% lesion rates in an animal model is pending publication. Noah Medical also received positive feedback from interventional pulmonologists and surgeons when demonstrating the system in the technology suite.
“Receiving the data and our hands-on technology sessions only further validates our approach to this market,” said Jian Zhang, PhD, Founder and CEO of Noah Medical. “Noah Medical was created to fill the gaps that exist with current robotic systems to deliver better patient outcomes and an enhanced customer experience.”
Noah Medical anticipates FDA clearance in 2023. To learn more about Noah Medical and the Galaxy System, please visit noahmed.com.
About Noah Medical
Noah Medical is building the future of medical robotics. Our next-generation robotic platforms and technologies target early diagnosis and treatment of patients in multiple indications. Based in Silicon Valley and backed by renowned institutional investors, our incredibly talented team of engineers, innovators and industry leaders bring years of experience from top robotics, medical device and healthcare companies. health in the world. Learn more at noahmed.com.
PR for Noah Medical